UNIVERSIDADE FEDERAL DE MINAS GERAIS

SynAct Pharma Launches Phase II Trial of Resomelagon for Dengue Treatment in Brazil

- SynAct Pharma has initiated the RESOVIR-2 study, a randomized Phase II trial evaluating resomelagon (AP1189) in 120 patients with dengue in Brazil, with no specific treatments currently available for the disease. - Resomelagon has demonstrated promising results in reducing dengue severity in animal models and decreasing proinflammatory activity in human white cells exposed to dengue virus, building on previous success in COVID-19 patients. - The study will assess resomelagon's efficacy through time to disease resolution and ability to reduce warning signs of severe dengue, potentially establishing a novel host-directed therapy approach for viral infections.